Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basaglar in youth with type 1 diabetes in Bangladesh
NCT06674135Phase 4Completed
- Sponsor
- Diabetes Australia
- Start
- Jun 2022
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine in type 1 diabetes mellitus (T1D), sponsored by Diabetes Australia. Primary endpoint: Hemoglobin A1c at 12 months. Started Jun 2022; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06674135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06674135.